Concurrent chemoradiotherapy using low-dose continuous infusion of 5-fluorouracil for postoperative regional lymph node recurrence of esophageal squamous cell carcinoma

被引：4

作者：

Tsuchida E. ^{[1
]}

Sakai K. ^{[1
,2
]}

Matsumoto Y. ^{[3
]}

Sugita T. ^{[3
]}

Sasamoto R. ^{[1
]}

Yamanoi T. ^{[1
]}

Sueyama H. ^{[4
]}

Ito T. ^{[5
]}

Sasai K. ^{[2
]}

机构：

[1] Dept. Molec. Genet., Course M., Grad. Sch. of Med. and Dent. Sci., Niigata University, Niigata 951-8510

[2] Niigata Rosai Hospital, Niigata

[3] Department of Radiology, Niigata Cancer Center Hospital, Niigata

[4] Department of Radiology, Niigata Prefectural Central Hospital, Niigata

[5] Department of Radiology, Nagaoka Red Cross Hospital, Niigata

来源：

Esophagus | 2005年 / 2卷 / 1期

关键词：

5-Fluorouracil; Chemotherapy; Esophageal cancer; Radiotherapy; Recurrence;

D O I：

10.1007/s10388-005-0035-7

中图分类号：

学科分类号：

摘要：

Background. Radiotherapy plays an important role in salvaging patients who suffer locoregional recurrence; however, it displays poor prognosis. Because concurrent chemoradiotherapy offers superior treatment results compared to radiotherapy alone in patients with localized esophageal cancer, to improve survival rates, we treated patients displaying postoperative regional lymph node recurrence of esophageal squamous cell carcinoma using radiotherapy combined with protracted low-dose continuous infusion of 5-fluorouracil (5-FU). Methods. Between January 1992 and December 2001, 14 patients with postoperative regional lymph node recurrence of esophageal squamous cell carcinoma were treated with concurrent chemoradiotherapy. Radiotherapy was delivered at 1.8-2.0 Gy/day, for a total dose of 56-70Gy (median, 60Gy). Chemotherapy was administered 5 days/week as continuous infusion of 5-FU (250-300mg/m2) for at least 5 weeks. Median follow-up time was 27 months. Results. Twelve patients demonstrated partial response, and 2 patients displayed stable disease. Response rate was therefore 86% (12/14). In-field recurrence occurred in 3 patients. Involved lymph nodes that recurred in the irradiation field were ≥40 mm in maximum diameter and invaded into the surrounding normal tissues. Local progression-free rate at 2 years was 72%. As an initial failure, 6 patients displayed out-field recurrence. Disease progression-free rate at 2 years was 42%. Overall survival rates at 1 and 2 years were 85% and 57%, respectively. Conclusions. Concurrent chemoradiotherapy using low-dose continuous infusion of 5-FU was effective for patients with postoperative regional lymph node recurrence of esophageal squamous cell carcinoma. Close follow-up is crucial, and further investigation is required to prevent outfield recurrence. © Japan Esophageal Society and Springer-Verlag 2005.

引用

页码：25 / 31

页数：6

共 19 条

[1]

Muller J.M., Erasmi H., Stelzner M., Zieren U., Pichlmaier H., Surgical therapy of oesophageal carcinoma, Br J Surg, 77, pp. 845-857, (1990)

[2]

Matsubara T., Ueda M., Takahashi T., Nakajima T., Nishi M., Localization of recurrent disease after extended lymph node dissection for carcinoma of the thoracic esophagus, J Am Coll Surg, 182, pp. 340-346, (1996)

[3]

Bhansali M.S., Fujita H., Kakegawa T., Yamana H., Ono T., Hikita S., Et al., Pattern of recurrence after extended radical esophagectomy with three-field lymph node dissection for squamous cell carcinoma in the thoracic esophagus, World J Surg, 21, pp. 275-281, (1997)

[4]

Shimada H., Kitabayashi H., Nabeya Y., Okazumi S., Matsubara H., Funami Y., Et al., Treatment response and prognosis of patients after recurrence of esophageal cancer, Surgery, 133, pp. 24-31, (2003)

[5]

Law S.Y.K., Fok M., Wong J., Pattern of recurrence after oesophageal resection for cancer: Clinical implications, Br J Surg, 83, pp. 107-111, (1996)

[6]

Chatani M., Matayoshi Y., Masaki N., Kabuto T., Radiation therapy for the supraclavicular lymph node metastasis after curative resection of the esophageal carcinoma, Strahlenther Onkol, 168, pp. 84-88, (1992)

[7]

Sakamoto N., Nishimura Y., Mitsumori M., Hiraoka M., Ono K., Abe M., Radiation therapy for recurrent esophageal carcinoma, J Jpn Soc Ther Radiol Oncol, 8, pp. 35-41, (1996)

[8]

Nemoto K., Ariga H., Kakuto Y., Matsushita H., Takeda K., Takahashi C., Et al., Radiation therapy for loco-regionally recurrent esophageal cancer after surgery, Radiother Oncol, 61, pp. 165-168, (2001)

[9]

Herskovic A., Martz K., Al-Sarraf M., Leichman L., Brindle J., Vaitkevicius V., Et al., Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus, N Engl J Med, 326, pp. 1593-1598, (1992)

[10]

Byfield J.E., Calabro-Jones P., Klisak I., Kulhanian F., Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and x rays, Int J Radiat Oncol Biol Phys, 8, pp. 1923-1933, (1982)

← 1 2 →